6505--Hydralazine Injection
ID: 36E79725R0048Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/c0cda927eace4d7e98b3c83fbefc4c5f/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Hydralazine Hydrochloride (HCL) injections as part of its Pharmaceutical Prime Vendor (PPV) Program. This contract aims to ensure the supply of U.S.-made pharmaceuticals that comply with federal regulations, including a 0.5% Cost Recovery Fee, and mandates that all offered products possess unique National Drug Code (NDC) numbers while adhering to U.S. manufacturing standards. The contract is crucial for maintaining the availability of essential medications for veterans, with a duration of one year and options for four additional years based on contractor performance. Interested contractors should submit their proposals, including pricing for both base and option years, to Nicholas I McGregor at Nicholas.McGregor@va.gov, ensuring compliance with the Drug Supply Chain Security Act (DSCSA) and other procurement guidelines.

    Point(s) of Contact
    Nicholas I McGregorContract Specialist
    Nicholas.McGregor@va.gov
    Files
    Title
    Posted
    36E79725R0048_1.docx
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0048, focusing on Hydralazine Hydrochloride Injections. This procurement is set aside for U.S.-made products only, in compliance with FAR 6.302-7 for public interest, and requires vendors to certify that their products meet U.S. manufacturing standards. The awarded contract will be for one year, with four additional one-year options, aimed at ensuring an uninterrupted supply for the VA's Pharmaceutical Prime Vendor Program. The estimated annual requirement includes 82,630 vials of 20 mg/mL Hydralazine HCL. Proposals will be accepted until August 29, 2025, with electronic issuance anticipated around July 29, 2025. Interested vendors are advised to check SAM.gov for updates. The point of contact for this procurement is Contracting Officer Nicholas McGregor, available for inquiries at Nicholas.McGregor@va.gov. This announcement underlines the VA's commitment to supporting U.S. manufacturers while providing critical medical supplies to veterans.
    36E79725R0048.docx
    The document outlines a solicitation by the Department of Veterans Affairs (VA) for the procurement of Hydralazine Hydrochloride (HCL) injections through the VA Pharmaceutical Prime Vendor (PPV) Program. The purpose is to establish a contract to provide U.S.-made pharmaceuticals, with an emphasis on compliance with federal regulations, including pricing that reflects a 0.5% Cost Recovery Fee. The solicitation includes specific requirements for offering products, such as unique National Drug Code (NDC) numbers, and mandates that all offered drugs meet U.S. manufacturing standards. Contractors must submit proposals that include prices for the base and option years, proving their capability to supply products through effective business-to-business agreements established with the PPV. The document also emphasizes compliance with the Drug Supply Chain Security Act (DSCSA), detailing requirements for serialization and record-keeping. An evaluation process for accepted proposals is established, highlighting the importance of prompt payment rules and accurate reporting. The contract duration is for one year with options for four additional years, contingent upon the contractor's performance and compliance with guidelines. Failure to fulfill contractual obligations could result in termination. Overall, this document serves as a comprehensive guide for potential contractors regarding the bidding process, contract requirements, and necessary compliance with U.S. federal procurement regulations.
    Lifecycle
    Title
    Type
    6505--Hydralazine Injection
    Currently viewing
    Solicitation
    6505--Hydralazine Injection
    Presolicitation
    Similar Opportunities
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    6505--LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB (VA-26-00008212)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking small business vendors to supply LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB, as part of solicitation number 36C77026Q0005. This procurement involves delivering a total of 1,460 boxes of the pharmaceutical product to the VA CMOP facility in Hines, Illinois, with a base period and four option years, each requiring delivery by January 5th of the respective year. The goods are critical for patient care within the VA healthcare system, emphasizing the importance of timely and compliant delivery. Interested vendors must submit their proposals, including a signed SF 1449, pricing schedule, and other required documentation, by December 16, 2025, at 3 PM Central Time, and can direct inquiries to Contract Specialist Jennifer Coleman at Jennifer.Coleman4@va.gov.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    Q517--FY26: VISN 8 Pharmacy Emergent First Fill Prescription Services
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 8 (NCO 8), is seeking qualified contractors to provide Emergent First Fill Prescription Services for VA beneficiaries within VISN 8, which includes locations in Florida and Puerto Rico. The procurement involves a Firm Fixed Indefinite Delivery Indefinite Quantity contract, covering a base period plus four option years, to deliver 24/7 pharmaceutical benefits management services, including filling new prescriptions and adhering to a specific emergency medication formulary. This service is crucial for ensuring timely access to medications for veterans in emergency situations, with strict requirements for confidentiality and compliance. Quotes are due by December 30, 2025, at 10:00 AM EST, and interested parties should direct inquiries to Contracting Officer Colleen Houser at colleen.houser@va.gov or by phone at 727-201-6880.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Nicotine Mini Lozenges, specifically under solicitation number 36E79726R0007. This contract aims to ensure an uninterrupted supply of nicotine lozenges for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with a contract duration of one year and four optional one-year extensions. The estimated annual requirements include 166,791 bottles of 2mg lozenges and 138,276 bottles of 4mg lozenges, which will be distributed through the VA and DOD Pharmaceutical Prime Vendor Programs. Interested offerors should note that the solicitation will be electronically issued around December 18, 2025, with a tentative closing date of January 1, 2026, and can direct inquiries to Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.